| Trial ID: | L1349 |
| Source ID: | NCT00936663
|
| Associated Drug: |
Placebo
|
| Title: |
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00936663/results
|
| Conditions: |
Type 2 Diabetes|End Stage Renal Disease
|
| Interventions: |
DRUG: Placebo|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Fasting Blood Glucose, Fasting blood glucose levels at 1 year, 1 year | Secondary: HbA1c, HbA1c at 1 year, 1 year|eGFR, estimated glomerular filtration rate (eGFR) at 1 year, 1 year|Hypoglycemia, Number of episodes of hypoglycemia (blood glucose less than 70 mg/dl), 1 year | Other: AUC for Glucose, Area Under the Curve for glucose after OGTT, 1 year|AUC for Insulin, Area Under the Curve for insulin after OGTT, 1 year|AUC for Proinsulin, Area Under the Curve for Proinsulin after OGTT, 1 year|AUC for C Peptide, Area Under the Curve for C peptide after OGTT, 1 year
|
| Sponsor/Collaborators: |
Sponsor: University of Nebraska
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
3
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-07-06
|
| Completion Date: |
2010-06-01
|
| Results First Posted: |
2018-04-24
|
| Last Update Posted: |
2023-09-13
|
| Locations: |
University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00936663
|
